OmniCyte is a preclinical stage biotechnology company based in Branford, CT, dedicated to developing targeted treatments for unmet needs in cancer therapy. With a focus on Immuno-Oncology Platform Technology, OmniCyte aims to address various indications including ovarian cancer, small cell lung cancer, non-small cell lung cancer, glioma, pancreatic cancer, prostate cancer, leukemia, and cancer stem cells.
Backed by a strong management team, advisors, and collaborators, OmniCyte has received funding from Connecticut Innovations, angel investors, NCI SBIR STTR, LLS Translational Research grants, and the founders. Their mission is to find life-saving treatments for patients with cancer by leveraging their proprietary technology and expertise in the field of oncology.
Generated from the website